pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention David Gilboa, the most common co-covered peer. We currently track 1 Biotech story that mention Warby Parker Inc., all published on February 27, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Warby Parker Inc.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention David Gilboa, the most common co-covered peer. We currently track 1 Biotech story that mention Warby Parker Inc., all published on February 27, 2026. Each carries 2 original sources on average.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Warby Parker Inc.. Shared-story counts are live from our verified record — not editorial picks.
Seer, Inc. and Warby Parker Inc. reported Q4 2025 results, highlighting a pivotal shift toward high-scale proteomics and clinical healthcare services respectively. While Seer focuses on deep-tech life sciences tools, Warby Parker is increasingly positioning itself as a primary eye care provider.
Warby Parker Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.